Ventas Stock: Is VTR Outperforming the Real Estate Sector?

Ventas Stock: Is VTR Outperforming the Real Estate Sector?

Aritra Gangopadhyay

Thu, September 17, 2026 at 4:49 PM GMT+3 2 min read

• VTR -1.16%
• XLRE -0.95%

Maryland-based Ventas, Inc. (VTR) is a healthcare real estate investment trust (REIT) that acquires, owns, and leases senior housing, life science, research & innovation (R&I), and healthcare properties. The company has a market cap of $45.2 billion and owns or operates approximately 1,450 properties in North America and the United Kingdom.

Companies with a market cap of $10 billion or more are typically called "large-cap stocks." VTR fits squarely into that category, with a market cap above this threshold that reflects its substantial size and influence in the healthcare facilities REIT industry.

More News from Barchart

However, the stock currently trades 13.2% below its 52-week high of $101.60 recorded on July 28. VTR has grown 5.2% over the past three months, outperforming the State Street Real Estate Select Sector SPDR ETF's (XLRE) 5.1% decline during the same time frame.

In the longer term, VTR has delivered a similar performance. The stock has grown 29.6% over the past 52 weeks, outpacing the 1.8% surge of XLRE over the same period. VTR has been trading above its 200-day moving average since last year and below its 50-day moving average since August.

On July 29, VTR announced the release of its better-than-expected Q2 2026 earnings. The company's revenue for the quarter amounted to $1.7 billion and surpassed the Street's forecasts. Additionally, its adjusted FFO for the period came in at $0.97, also topping the consensus estimates. Ventas expects full-year funds from operations in the range of $3.85 to $3.90 per share.

When stacked against its rival, Healthpeak Properties, Inc. (DOC) has grown 13.1% over the past year, lagging behind VTR.

Wall Street has a highly bullish view of the stock currently. Among the 23 analysts tracking VTR, the overall consensus stands at a "Strong Buy." Its mean price target of $102 suggests a 15.7% upside potential from current price levels.

On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com